Mezoteliomi
Mesotheliomas
Keywords:
malignant mesotheliomaAbstract
Maligni mezoteliom uvrščamo med redke rake, njegova incidenca pa še vedno narašča pri nas in v svetu. V Sloveniji smo zakonsko prepovedali proizvodnjo in uporabo azbesta leta 1996, vendar še nismo zmanjšali bremena te bolezni, ker je latentni čas med izpostavljenostjo azbestu ter obolevnostjo zelo dolg. Različne klinične raziskave so potrdile učinkovitost sistemskega zdravljenja, kot sta kombinaciji cisplatina in gemcitabina ter cisplatina in pemetrekseda. Do sedaj smo samo na Nizozemskem in v Sloveniji dokazali, da je sodobno kemoterapevtsko zdravljenje statistično značilno podaljšalo srednje celokupno preživetje celotne populacije bolnikov s to boleznijo.Abstract (Eng)
Malignant mesothelioma is a rare type of cancer, the incidence of which is still increasing both in our country and also throughout the world. In Slovenia, the production and use of asbestos was prohibited in 1996, but we have not yet managed to reduce the burden of this disease due to the extremely long latency period between exposure to asbestos and incidence of the disease. Different clinical trials confirmed the effectiveness of systemic treatment, such as the combination of cisplatin and gemcitabin and the combination of cisplatin and pemetrexed. So far, only the Netherlands and Slovenia have managed to prove that modern chemotherapy treatment statistically significantly prolonged the median overall survival of the entire population of patients with this disease.Downloads
Published
How to Cite
Issue
Section
License
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.









